Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients

Simcere

Status and phase: Completed; Phase 3

Conditions: Extensive-stage Small-cell Lung Cancer

Treatments: Drug: placebo, carboplatin, etoposide，or Topotecan; Drug: Trilaciclib, carboplatin, etoposide，or Topotecan

Study type: Interventional

Funder types: Industry

Identifiers

NCT04902885

B02B00801-TRILA-301

Details and patient eligibility

About

A Randomized, double-blind, placebo-controlled, multi-center Phase 3 study evaluating efficacy, safety and pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients Receiving Carboplatin combined with Etoposide or Topotecan The study consists of 2 parts: Part 1: safety run-in and pharmacokinetics evaluation of 12 ES-SCLC patients (6 each for first line and second/third line ES-SCLC patients); Part 2: randomized, double-blind, placebo-controlled efficacy confirmation study of 80 ES-SCLC patients (stratified by first line and second/third line ES-SCLC, ECOG PS [0-1 vs 2] and brain metastases.

The study includes screening period, treatment period, safety follow-up and survival follow-up.

Full description

This is a multi-center Phase 3 clinical trial with an open-label single-arm safety run-in and PK evaluation part and a randomized double-blind, placebo controlled part in patients with ES-SCLC to evaluate the safety, efficacy, and pharmacokinetic profile of Trilaciclib based on completed clinical studies abroad.

The study consists of 2 parts. The first part, safety run-in and PK evaluation, enrolled approximately 12 patients with extensive-stage small-cell lung cancer, 6 patients each with 1st line ES-SCLC and 2nd/3rd line ES-SCLC to receive Trilaciclib in combination with carboplatin and etoposide (EC regimen) or with topotecan, and based on evaluable data from Cycle 1, evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy (prevention of myelosuppression) of Trilaciclib. The second part is a randomized double-blind, placebo-controlled efficacy validation study, and approximately 80 patients with ES-SCLC will be enrolled in Part II, stratified by 1st line vs 2nd/3rd line ES-SCLC, ECOG PS (0-1 vs 2), and presence vs absence of brain metastases, and randomized in a 1:1 ratio to Trilaciclib and placebo, in which patients with 1st line ES-SCLC receive Trilaciclib/placebo combined with EC regimen (Trilaciclib-EC group and placebo-EC group), and patients with 2nd/3rd line ES-SCLC receive Trilaciclib/placebo combined with topotecan (Trilaciclib-TPT group and placeboTPT group), and the efficacy of Trilaciclib (prevention of myelosuppression) will be evaluated with duration of severe neutropenia (DSN) in Cycle 1 as the primary endpoint. The planned dose of Trilaciclib is 240 mg/m2. If the safety data from the first part of the study suggest that the dose of Trilaciclib needs to be adjusted, 12 additional patients (6 patients each for 1st line ES-SCLC and 2nd/3rd line ESSCLC) will be enrolled in the first part of the study to explore the PK and safety of Trilaciclib 200 mg/m2. The study process includes screening period, treatment period, safety followup and survival follow-up.

The end of the study was defined as death in 75% of subjects, or 12 months after the last subject was enrolled, or the sponsor decided to terminate the study, whichever came first.

Enrollment: 95 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age ≥ 18 years, male or female;

2. Histologically or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC):

   • Patients scheduled to receive carboplatin plus etoposide regimen: no prior systemic therapy (eg, chemotherapy or combined with immunotherapy);
   • Patients scheduled to receive topotecan regimen: previously received 1/2 lines of chemotherapy or combined immunotherapy but not topotecan.

3. Presence of at least one radiation-naïve measurable lesion according to RECIST 1.1 criteria;

4. Hemoglobin ≥ 90 g/L;

5. Neutrophil count ≥ 1.5 × 10^9/L;

6. Platelet count ≥ 100 × 10^9/L;

7. Creatinine ≤ 15 mg/L or creatinine clearance (CrCl) ≥ 60 mL/min (Cockcroft-Gault formula);

8. Total bilirubin ≤ 1.5 × upper limit of normal (ULN);

9. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN or ≤ 5 × ULN (for patients with liver metastases);

10. Albumin ≥ 30 g/L;

11. ECOG PS score 0 - 2;

12. Expected survival time ≥ 3 months;

13. Contraception:

    Females: All females of childbearing potential must have a negative serum pregnancy test at screening and must use reliable contraception from signing of informed consent through 3 months after the last dose; Male: Female partners of childbearing potential must use reliable contraception from signing the informed consent until 3 months after the last dose;

14. Understand and sign informed consent

Exclusion criteria

1. Symptomatic brain metastases requiring local radiotherapy or hormonal therapy;
2. History of other malignancies, with the following exceptions: (1) clinically cured cutaneous basal cell or squamous cell tumors; (2) cured a) cervical cancer, b) prostate cancer, c) superficial bladder cancer; or (3) other solid tumors with a clinical cure time of more than 3 years;
3. Uncontrolled ischemic heart disease or clinically significant congestive heart failure (NYHA Class III or IV);
4. Stroke or cardiovascular or cerebrovascular event within 6 months prior to enrollment;
5. Severe active infection;
6. Psychological or other social factors causing insufficient trial compliance;
7. Other uncontrolled serious chronic diseases or conditions that, in the opinion of the investigator, would make participation in the trial inappropriate;
8. Known HIV infection, active hepatitis B (defined as positive HBV DNA), and hepatitis C (positive HCV RNA);
9. Radiation therapy within 2 weeks prior to enrollment;
10. Patients who have received cytotoxic drug therapy or investigational drug therapy within 4 weeks before enrollment, or non-cytotoxic anti-tumor drug therapy within 2 weeks;
11. Subjects in the first part of the study should not take strong or moderate inducers of CYP3A4 concomitantly within 4 weeks before taking the study drug, and strong inhibitors of CYP3A4 concomitantly within 2 weeks before taking the study drug;
12. Toxicity from prior anticancer therapy has not recovered to Grade 0 or 1 (except alopecia);
13. Hypersensitivity to the study drug (Trilaciclib, etoposide, carboplatin, topotecan) or components thereof;
14. Persons who are unable to act independently due to legal restriction or legal sense;
15. Pregnant or lactating women;
16. Not suitable for participating in this study in the investigator 's opinion.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

95 participants in 3 patient groups, including a placebo group

Part I ( Safety run-in and PK Evaluation); Trilaciclib Group

Active Comparator group

Description:

12 patients( 6 patients are first line, 6 patients are second or third line) recieved Trilaciclib(240mg/m\^2) plus chemotherapy.

Treatment:

Drug: Trilaciclib, carboplatin, etoposide，or Topotecan

Part II ( Randomized Double-blind, Placebo-controlled ), Trilaciclib Group

Active Comparator group

Description:

41 patients received trilaciclib(240mg/m\^2) plus chemotherapy

Treatment:

Drug: Trilaciclib, carboplatin, etoposide，or Topotecan

Part II ( Randomized Double-blind, Placebo-controlled ), Placebo Group

Placebo Comparator group

Description:

42 patients received placebo plus chemotherapy

Treatment:

Drug: placebo, carboplatin, etoposide，or Topotecan